Effects of losartan on left ventricular mass: a three-year follow-up in elderly hypertensives with myocardial hypertrophy despite successful conventional antihypertensive treatment.

OBJECTIVE: Reversal of left ventricular hypertrophy (LVH) in hypertensive patients appears to be a desirable goal to the reduction cardiac risk. The Renin-Angiotensin System (RAS) seems to play a major role in the establishment and maintenance of LVH through the activated systemic RAS and the Intracardiac Angiotensin System (IAS). We focused on the effects of a three-year treatment with losartan supplement in hypertensive patients with LVH not responding to eight years of an effective previous antihypertensive pharmacological treatment. PATIENTS AND METHODS: Two groups of 28 sex-, age- and therapy-matched subjects with essential hypertension and LVH were taken into consideration. The two groups were in effective pharmacological treatment (BP < 140/90) for eight years previous to their enrollment. Patients of Group A were treated for three years with a losartan (100 mg/die) on-top treatment, whereas patients of Group B continued the follow-up of the previous conventional therapy. Both groups were submitted to an echocardiographic follow-up. RESULTS: Group A, showed a significant reduction of the mean LVH since the first step at six months with a further significant trend during the whole period (variance analysis: p < 0.001). Group B showed a non-significant trend toward LVH reduction during the three-year follow-up. No significant further reduction of systolic or diastolic blood pressure values was observed in both groups. CONCLUSIONS: The effects of losartan in hypertensive and hypertrophic patients are in agreement with the results of LIFE Trial. However, the reduction of left ventricular hypertrophy in our patients seems to be related to changes inducted by losartan on the IAS, since no further hemodynamic effects were observed. Losartan induced both a significant reduction of LVH and an improvement of LV diastolic function with a subsequent expected beneficial shift on the prognosis.

Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients.

OBJECTIVE: Transsphenoidal surgery results in biochemical remission of acromegaly in 45-80% of patients; however, few studies have addressed the impact of transsphenoidal surgery on cardiovascular function in acromegalic patients. The aim of this prospective study was to investigate the effects of postoperative GH/IGF-I normalization on echocardiographic parameters and blood pressure (BP) in a series of patients with active acromegaly. DESIGN: An open prospective study. PATIENTS: Thirty newly diagnosed acromegalic patients undergoing transsphenoidal surgery. MEASUREMENTS: Doppler echocardiography and 24-h ambulatory blood pressure monitoring were performed before and 6 months after transsphenoidal surgery. RESULTS: Fifteen patients were considered to be well controlled postoperatively (group A), as defined by normal age-corrected IGF-I levels and glucose-suppressed GH levels less than 2 mU/l, the remaining 15 patients being considered as poorly controlled (group B). In group A, a postoperative decrease of left ventricular mass index was observed (104.4 +/- 6.6 vs. 127.1 +/- 7.7 g/m2; P < 0.001), associated with an improvement of some indices of diastolic function, such as an increase of the early/late transmitral peak flow velocity (P < 0.05) and a decrease of isovolumic relaxation time (P < 0.01). No significant change was observed in group B. A significant decrease of 24-h systolic BP was also observed in group A (P < 0.05) and five of six patients normalized their BP circadian rythm. In contrast, a nonsignificant increase in BP values, with a persistent blunted BP profile where present, was observed in group B. CONCLUSIONS: We conclude that successful transsphenoidal surgery is able to induce a significant improvement in some cardiac parameters and a slight reduction in systolic blood pressure in acromegalic patients.

Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.

OBJECTIVES: To determine whether highly active antiretroviral therapy (HAART) is effective in HIV-associated neurocognitive impairment. DESIGN: An open label, prospective, observational study. METHODS: Since April 1996, 116 patients with advanced HIV infection, reverse transcriptase inhibitor (nRTI) experienced but protease inhibitor (PI) naive, were screened for the presence of neurocognitive impairment. Ninety patients with confounding neurological illness, opportunistic infections or drug abuse were excluded. The remaining 26 patients underwent comprehensive neuropsychological testing, and laboratory measures before, after 6 and after 15 months of treatment with one PI plus two nRTI. RESULTS: The prevalence of neurocognitive impairment decreased from 80.8% (baseline) to 50.0% (P<0.05) (sixth month) and to 21.7% (P<0.001) (15th month). Among the functions explored, the impairment of concentration and speed of mental processing decreased from 65.4 to 21.7% (P<0.01) and of memory impairment from 50 to 8.7% (P<0.01). Comparing baseline with the sixth and 15th month raw scores, a statistically significant improvement was seen in measures exploring concentration and speed of mental processing (P<0.05), mental flexibility (P<0.05), memory (P<0.05), fine motor functions (P<0.05) and visuospatial and constructional abilities (P<0.01). After 6 months of HAART patients with a normal neuropsychological examination had lower mean plasma viraemia (2.95 versus 3.97 log copies/ml, P<0.05) and greater mean log plasma HIV RNA changes from baseline (-1.84 versus -0.83 log copies/ml, P<0.05) than neuropsychologically impaired subjects. CONCLUSION: HAART produces a positive and sustained effect on neurocognitive impairment in HIV-infected patients. A reduction of plasma viral load was associated with the regression of neuropsychological test abnormalities.

99mTc-sestamibi and 201-Thallium at rest: dual scintigraphic mapping of myocardial injury in infarcted patients.

UNLABELLED: 201-Thallium (Tl) and (99m)Tc-sestamibi (SM) present different biological properties and kinetics, suggesting a complementary evaluation of mitochondrial and cell membrane functions with subsequent implications regarding myocardial injury mapping. To verify the usefulness of a dual isotopic approach in Q infarcted patients, 30 subjects were submitted at rest, within 5 days, to SM imaging, 4h-delayed Tl scans and echocardiography (ECHO). Left ventricle segmental uptake and wall motion were graded on a 3 points scale (0=absent to 2=normal) and compared on the basis of an 11 segments model. RESULTS AND DISCUSSION: 1) The analysis of SM normal segments demonstrated a strong concordance (97%) with Tl and ECHO, suggesting that both mitochondrial and cell membrane functions are preserved; 2) 49% of SM graded 0 segments were scored 1 by Tl and ECHO, suggesting a worse impairment of mitochondrial function with respect to cell membrane function; 3) approximately 55% of segments showing a reduced MIBI uptake were found normal using Tl, then an impaired mitochondrial but a normal cell membrane function could be hypothesized. 4) Tl provided a better estimation of the effective infarction size with respect to SM. CONCLUSIONS: The SM and Tl dual approach, allowing scintigraphic mapping of myocardial injury, seems to provide a useful tool for a complete evaluation of infarcted patients.

Clinical features of subjects with mitral valve prolapse: a study with 24-hour ambulatory blood pressure monitoring.

The present case-control study provides evidence that the correlation between mitral valve prolapse and the clinical observation of low blood pressure persists throughout a 24-hour period as documented by ambulatory blood pressure monitoring. Moreover, the blood pressure circadian rhythm, even though preserved, seems to follow a different course over the 24-hour period in subjects with mitral valve prolapse.

Sestamibi imaging and echocardiography: a combined approach to myocardial infarction.

The resting relationship of MIBI segmental uptake to regional wall motion has been studied in 30 patients with postinfarction wall motion abnormalities. The purpose of this study was to verify whether an integrated approach using Sestamibi (MIBI) imaging (perfusion analysis) combined with echocardiography (ECHO) (wall motion analysis) could present an additive value to differentiate infarcted from viable myocardial areas with respect to MIBI imaging alone. The same 11 segments model for left ventricle was used to compare segmental wall motion scores versus segmental uptake scores using a chi 2 analysis. The global score frequency rates for MIBI and ECHO were examined and a subsequent comparative analysis score versus score on each segment was performed. Our data, based on a chi 2 analysis, indicated that MIBI imaging overestimates the effective area of necrosis, underestimating, furthermore, hypoperfused but non-necrotic myocardium. We can conclude that an integrated approach based on both segmental perfusion and wall motion analysis, seems to be clinically suitable for a correct evaluation of infarcted patients, especially in view of revascularization procedures, providing an additive value in discriminative capacity, with respect to MIBI scintigraphic analysis alone.

[Clinical use of echo-dipyridamole test in hypertensive subjects with suspected ischemic heart disease]. / Impiego clinico del test eco-dipiridamolo in soggetti ipertesi con sospetta cardiopatia ischemica.

The aim of this study was to assess the diagnostic capacity of the dipyridamole-echocardiography test (DET) and dipyridamole myocardial scintigraphy (DMS) for coronary artery disease in mild to moderate hypertensive subjects with chest pain. A comparison was performed with exercise stress test (EST) and stress myocardial scintigraphy (SMS) in 20 subjects. Seven patients also underwent coronary angiography. To compare test results, Mc Nemar test was employed. Our results showed a statistically significant difference between DET and EST and a good agreement, in terms of dichotomy response, between DET and SMS. Any difference was further found between SMS and DMS. In conclusion, in hypertensive subjects, DET appears to provide a useful clinical noninvasive tool for coronary artery disease diagnosis and evaluation.

P300 variations in parkinsonian patients before and during dopaminergic monotherapy: a suggested dopamine component in P300.

P300 was recorded, using an 'odd ball' paradigm, in 18 parkinsonian patients before and during dopaminergic monotherapy. The data were compared with those of a homogeneous standard group of 20 subjects. The main finding was an increase in the P300 latency of parkinsonian patients before therapy, which recovered during dopaminergic monotherapy. In 11 voluntary healthy subjects the same therapy did not produce a reduction of the P300 latency. The data are discussed in relation to a possible dopaminergic component in P300 origin.

Early auditory evoked potential changes during hypoxic hypoxia in the rabbit.

Early auditory evoked potentials and electroencephalograms were recorded in 10 rabbits during hypoxic hypoxia (5% O2 in N2 gas mixture) and after reoxygenation. In all experiments EEG flattening preceded the disappearance of the early evoked potential, whose recovery after reoxygenation was more rapid than that of the EEG. Significant increases in P3-P4 and P1-P3 interpeak latencies were observed during hypoxic conditions before the complete flattening of the early auditory evoked potential. In addition, negative relationships were found between the P3-P4 interpeak latency increase and mean arterial pressure reduction, and between the former and metabolic acidosis.